• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bright Minds Biosciences Inc.

    10/23/24 6:09:07 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRUG alert in real time by email
    SC 13G 1 drug13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)

    Bright Minds Biosciences Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    10919W405

    (CUSIP Number)

    October 16, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 10919W405

     

     

    1.Names of Reporting Persons.

    Logos Global Management LP

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 100,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 100,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 100,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) IA, PN

     2 
    CUSIP No. 10919W405

     

     

    1.Names of Reporting Persons.

    Logos Global Management GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 100,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 100,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 100,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) HC, OO

     

     3 
    CUSIP No. 10919W405

     

     

    1.Names of Reporting Persons.

    Arsani William

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 100,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 100,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 100,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 10919W405

     

     

    1.Names of Reporting Persons.

    Logos Global Master Fund LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ___X__

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 100,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 100,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 100,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     5 
    CUSIP No. 10919W405

     

     

    1.Names of Reporting Persons.

    Logos GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 100,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 100,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 100,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 2.2%

     

    12.Type of Reporting Person (See Instructions) OO

     

     6 
    CUSIP No. 10919W405

     

     

    Item1.
    (a)Name of Issuer

    Bright Minds Biosciences Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    19 Vestry Street, New York, NY 10013

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    Logos Global Master Fund LP (“Global Fund”), Logos Global Management LP (“Logos Global”), Logos GP LLC (“Logos GP”), Logos Global Management GP LLC (“Logos Global GP”), and Arsani William (collectively, the “Filers”).

     

    Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Dr. William is a control person of Logos Global and Logos Global GP.

     

    The Filers are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. In addition, filing this Schedule 13G on behalf of Global Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Shares.

     

    (e)The CUSIP number of the Issuer is: 10919W405.
     7 
    CUSIP No. 10919W405

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to Logos Global.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G) as to Logos Global GP and Dr. William.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The Filers acquired beneficial ownership of 300,000 Common Shares on October 16, 2024, which represented more than five percent of the outstanding Common Shares. However, as a result of subsequent transactions, the Filers’ beneficial ownership declined below five percent as of the date of this Schedule 13G.

     

    The percentages reported in this Schedule 13G are based on 4,463,837 Common Shares outstanding as of June 30, 2024, as reported in the Management’s Discussion and Analysis filed by the Issuer as an Exhibit to the Form 6-K on August 15, 2024.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Global Fund holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of Logos Global, Logos Global GP and Dr. William:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Global Fund and Logos GP:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. 10919W405

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: October 23, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     

    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William

    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William

    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William

    Title: Managing Member

     9 
    CUSIP No. 10919W405

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: October 23, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     

    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William

    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William

    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William

    Title: Managing Member

     

    Get the next $DRUG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRUG

    DatePrice TargetRatingAnalyst
    5/13/2025Buy
    TD Cowen
    5/7/2025$80.00Buy
    Chardan Capital Markets
    1/23/2025$93.00Overweight
    Piper Sandler
    1/10/2025Overweight
    Cantor Fitzgerald
    1/10/2025$85.00Buy
    H.C. Wainwright
    11/26/2024$75.00Outperform
    Robert W. Baird
    More analyst ratings

    $DRUG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      11/6/24 4:20:48 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:11:29 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Cormorant Asset Management, Lp claimed ownership of 452,409 shares (SEC Form 3)

      3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:07:59 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bright Minds Biosciences Inc.

      SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/12/24 4:15:24 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bright Minds Biosciences Inc.

      SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/6/24 4:06:00 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bright Minds Biosciences Inc.

      SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/5/24 3:25:38 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

      - BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101's potential to address critical gaps in SUDEP prevention - NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced positive findings from its DBA/2 mouse model study. BMB-101, the Compan

      5/13/25 8:30:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

      VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET. The event will provide an overview of absence seizures and will focus on the unmet need in this group of epilepsy patients. The webcast will include presentations from renowned Key Opinion Leaders (KOLs) in epilepsy research, as well as an overview of the Company'

      4/28/25 8:00:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

      – Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company's clinical focus on epilepsy – VANCOUVER, British Columbia, March 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced the expansion of its Scientific Advisory Board (SAB) to include five distinguished experts in epi

      3/4/25 8:00:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    SEC Filings

    See more
    • SEC Form 6-K filed by Bright Minds Biosciences Inc.

      6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

      4/28/25 7:05:39 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Bright Minds Biosciences Inc.

      SCHEDULE 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      4/8/25 3:14:41 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

      SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      4/7/25 4:07:58 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Bright Minds Biosciences

      TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy

      5/13/25 9:38:46 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Bright Minds Biosciences with a new price target

      Chardan Capital Markets initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $80.00

      5/7/25 8:37:12 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bright Minds Biosciences with a new price target

      Piper Sandler initiated coverage of Bright Minds Biosciences with a rating of Overweight and set a new price target of $93.00

      1/23/25 7:40:15 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      11/6/24 4:20:48 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:11:29 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Leadership Updates

    Live Leadership Updates

    See more

    $DRUG
    Financials

    Live finance-specific insights

    See more
    • Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

      -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an

      1/7/25 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

      -- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a

      2/27/23 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Announces Resignation of Board Member

      VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br

      1/9/23 4:05:00 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

      -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.

      4/19/22 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care